Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:approves |
gptkb:2020
gptkb:European_Union gptkb:United_States |
| gptkbp:bioavailability |
~60%
|
| gptkbp:can_be_combined_with |
gptkb:cobimetinib
gptkb:trametinib |
| gptkbp:casnumber |
606143-52-6
|
| gptkbp:chemical_formula |
C16 H14 F3 N3 O3 S
|
| gptkbp:clinical_trial |
Phase III
NCT02039900 NCT01362803 NCT02989857 NCT01718165 |
| gptkbp:developed_by |
gptkb:Astra_Zeneca
|
| https://www.w3.org/2000/01/rdf-schema#label |
selumetinib
|
| gptkbp:indication |
gptkb:neurofibromatosis_type_1
gptkb:Oncology unresectable or metastatic melanoma |
| gptkbp:marketed_as |
gptkb:Koselugo
|
| gptkbp:mechanism_of_action |
MEK inhibitor
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
fatigue
nausea diarrhea rash elevated liver enzymes |
| gptkbp:targets |
gptkb:MEK1
gptkb:MEK2 |
| gptkbp:used_for |
treatment of cancer
|
| gptkbp:bfsParent |
gptkb:Cotellic
|
| gptkbp:bfsLayer |
6
|